GlassScriptPhysician profile
Christopher Michael Calzetta
NPI 1780224600
$7,284.79
in general payments reported to CMS, 2019-2025
21 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,548 · 2022: $2,361 · 2023: $1,321 · 2024: $838 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,264 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,264.10 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,456.72 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $1,102.00 | 2021-2024 | Spravato, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $822.57 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $461.14 | 2021-2025 | Abilify Mycite, Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $446.74 | 2021-2023 | |
| Alkermes, INC. | $392.87 | 2021-2024 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $307.22 | 2021-2025 | Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $264.64 | 2021-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $221.67 | 2021-2023 | Belsomra |
| Neurocrine Biosciences, INC. | $181.05 | 2021-2023 | Ingrezza |
| Axsome Therapeutics, INC. | $123.15 | 2022-2025 | Auvelity |
| Eisai INC. | $114.32 | 2021 | |
| Indivior INC. | $86.21 | 2022-2023 | Sublocade, Perseris |
| Lundbeck LLC | $80.93 | 2021-2024 | Abilify Asimtufii |
| Idorsia Pharmaceuticals US INC | $58.98 | 2022-2023 | Quviviq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $46.57 | 2021-2022 | |
| Tris Pharma INC | $34.46 | 2023 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $32.67 | 2025 | Fanapt |
| Avanir Pharmaceuticals, INC. | $20.42 | 2021 | |
| Bausch Health US, LLC | $15.53 | 2022 | |
| Boston Scientific Corporation | $14.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Calzetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.